Enzalutamide (MDV3100)

Catalog No.S1250

For research use only.

Enzalutamide (MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM in LNCaP cells. Enzalutamide is shown to increase autophagy.

Enzalutamide (MDV3100) Chemical Structure

CAS No. 915087-33-1

Selleck's Enzalutamide (MDV3100) has been cited by 418 publications

Purity & Quality Control

Choose Selective Androgen Receptor Inhibitors

Other Androgen Receptor Products

Biological Activity

Description Enzalutamide (MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM in LNCaP cells. Enzalutamide is shown to increase autophagy.
Targets
Androgen Receptor [1]
(LNCaP cells)
36 nM
In vitro

Enzalutamide has greater affinity to AR than Bicalutamide does in a competition assay with 16β-[18F]fluoro-5α-DHT (18-FDHT) in castration-resistant LNCaP/AR cells (AR-overexpressing). While Enzalutamide shows no agonism in LNCaP/AR prostate cells. Enzalutamide antagonizes induction of prostate-specific antigen (PSA) and transmembrane serine protease 2 (TMPRSS2), combination with the synthetic androgen R1881 in parental LNCaP cells. Enzalutamide could inhibit the transcriptional activity of a mutant AR protein (W741C, mutation of Trp741 to Cys). [1] Enzalutamide also prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human LNCAP MnvQR5l1d3SxeHnjJGF{e2G7 NWDWOFBZPyCmYYnz M2Hwd|k2LSCHdF;I NFGzR2xKSzVyPUWuNVIh|ryP MkX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MUO1OlcoRjJ|N{GzOVY4RC:jPh?=
human LNCAP NYWyOGpjTnWwY4Tpc44hSXO|YYm= NFHtUHMyKM7:TR?= NGnGSnVFVVOR NYeyeFlOUW6qaXLpeJMheHKxc4TheIUhe3CnY3nmbYMh[W62aXflckB{\WO{ZYTpc44hcW5iaIXtZY4hVE6FQWCgZ4VtdHNiZYjwdoV{e2mwZzDhcoRzd2enbjDy[YNmeHSxcjDheEAyODBvMUCwNI5O NF36T|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEKxPFcyPyd-MkCyNVg4OTd:L3G+
VCaP MVXGeY5kfGmxbjDBd5NigQ>? NFr5T40yOCEQvF2= MlnSNlQhcA>? MUHEUXNQ MVnTeZBxemW|c3XzJIxq\2GwZD3t[YRq[XSnZDDBVk1HVCC|aXfuZYxqdmd? MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjdzMESzOkc,OjJ5MUC0N|Y9N2F-
BCK4 MkPOSpVv[3Srb36gRZN{[Xl? NULjTZljOTBizszN MUe3JIRigXN? M4LrZ2ROW09? NFTqVHBKdmirYnn0d{Bme3S{YXTpc4wudWWmaXH0[YQheHKxbHnm[ZJifGmxbh?= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR3MUGwPUc,OjR2NUGxNFk9N2F-
MCF7s NIH5N2dHfW6ldHnvckBCe3OjeR?= MXqxNEDPxE1? MUK2JIRigXN? NVnEWVJ1TE2VTx?= M{Xo[mlvcGmkaYTzJIV{fHKjZHnvcE1u\WSrYYTl[EBxem:uaX\ldoF1cW:w MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR3MUGwPUc,OjR2NUGxNFk9N2F-
PC-3 MlfkSpVv[3Srb36gRZN{[Xl? NHfOcIgyOCEQvF2= MYK3NkBp NYX5[m9vTE2VTx?= M1vI[GRw\XNibn;0JIlvcGmkaYSgZ4VtdCCycn;sbYZmemG2aX;u NGX4TYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO0OFg3PCd-MkWzOFQ5PjR:L3G+
CWR22Rv1 M3HmUmZ2dmO2aX;uJGF{e2G7 MUCxOUDPxE1? MVmyOEBp MlHLSG1UVw>? MVTEc4V{KG6xdDDh[oZm[3RidHjlJIZ2dGxibHXu[5RpKEGUIHX4dJJme3Orb36= NUToPGgzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NVM2PjdpPkKzO|E{PTZ5PD;hQi=>
LNCAP/AR MXzBcpRi\2:waYP0JIFkfGm4aYT5JIF{e2G7 NVjSXoxxUUN3MDC9JFAvODJzIN88US=> MlXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5MUe1OFQoRjJ5N{G3OVQ1RC:jPh?=
MDA-MB-453 MV\BcpRi\2:waYP0JIFkfGm4aYT5JIF{e2G7 MlzNSWM2OCB;IECuNFQ6KM7:TR?= MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdzM{W2O{c,OjN5MUO1Olc9N2F-
LNCAP MYTBcpRi\2:waYP0JIFkfGm4aYT5JIF{e2G7 NIGyVI84OiCq M3vTWGlEPTBiPTCwMlA2KM7:TR?= NX\BT|VNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxPVMzOTVpPkOwNVk{OjF3PD;hQi=>
LNCAP NYL0[lhPSW62YXfvcol{fCCjY4Tpeol1gSCjc4PhfS=> MVi3NkBp NHLsTWdKSzVyIE2gNE4xQSEQvF2= Mon6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzOUOyNVUoRjNyMUmzNlE2RC:jPh?=
LNCAP MmT1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIr3SnBIUTVyIE2gNE4yOiEQvF2= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDBzMUKxPUc,OjhyMUGyNVk9N2F-
LNCAP MX7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? M4XiSFMh\GG7cx?= M2fLeWlEPTBiPTCwMlEzPzFizszN NUXR[29wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOFY{OTNpPkK2NFQ3OzF|PD;hQi=>
LNCAP M2nzPWFvfGGpb37pd5Qh[WO2aY\peJkh[XO|YYm= NX7H[pI6PiCmYYnz M2H4WWdKPTBiPTCwMlI6KM7:TR?= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDBzMUKxPUc,OjhyMUGyNVk9N2F-
UAS-bla GripTite 293 MWLBcpRi\2:waYP0JIFkfGm4aYT5JIF{e2G7 NYLEXpdlOTZidH:gNlQhcA>? NF3wT|hKSzVyIE2gNE4{PjFizszN MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzNyMUO2PEc,Ojd|MEGzOlg9N2F-
mammalian expression system NE\VUVlCdnSjZ3;ubZN1KGGldHn2bZR6KGG|c3H5 NEPKWXgzOiC2bzCyOEBp MWnFR|UxKD1iMD60NkDPxE1? NFvkVZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO4OVUxOyd-MkizPFU2ODN:L3G+
VCaP NWjLeG5vT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX\re3NlOTR2IHi= M3vYcmdKPTBiPTCwMlYyKM7:TR?= MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{MUW4Okc,OjVzMkG1PFY9N2F-
LNCaP MmHERY51[WexbnnzeEBi[3Srdnn0fUBie3OjeR?= MUWyJIg> MXjFR|UxKD1iMD65NVUh|ryP M{\KOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{GzOVY4Lz5{M{exN|U3PzxxYU6=
COS7 MnPMRY51[WexbnnzeEBi[3Srdnn0fUBie3OjeR?= NULjTHhoOjRiaB?= M2m0OWlEPTBiPTCxMlI3KM7:TR?= NYrY[VA2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxNVc5QTdpPkK5NVE4QDl5PD;hQi=>
AR LBD mutant MVrBcpRi\2:waYP0JIFkfGm4aYT5JIF{e2G7 NXv6c5dTPCCq NHi2TVlKSzVyIE2gNU4{PSEQvF2= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzhzMEW4PUc,Ojd6MUC1PFk9N2F-
LNCAP M4HuNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX3HTVUxKD1iMj64PEDPxE1? NYjXV3BkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N|QyOzBpPkK1OlM1OTNyPD;hQi=>
CWR22Rv1 MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlLsS2k2OCB;IEOuN|Qh|ryP MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ|NEGzNEc,OjV4M{SxN|A9N2F-
LNCAP NHHkSXREgXSxdH;4bYNqfHliYYPzZZk> NVn4eWltPyCmYYnz NFP4WoJIUTVyIE2gOU4yOiEQvF2= M4fYflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{GzOVY4Lz5{M{exN|U3PzxxYU6=
PC3 NXyxboxRT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkP3S2k2OCB;IEmuNVUh|ryP NIHVdWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zOFE{OCd-MkW2N|QyOzB:L3G+
CWR22Rv1 NWnZPFhuS2WubDDzeZJ3cX[jbDDhd5NigQ>? MYOxOFQhcA>? M4POfGlEPTBiPTC5Mlch|ryP M3OxUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKxOVg3Lz5{NUGyNVU5PjxxYU6=
LNCAP NX\kT2dDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NILablI6PiCq NYfWbZBlUUN3MDC9JFEyNjR5IN88US=> NX7nVI4xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezNFE{PjhpPkK3N|AyOzZ6PD;hQi=>
LNCaP-hr MW\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NXvQfGlzOyCmYYnz M4T4eGlEPTBiPTCxNk42KM7:TR?= Mk\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MUC1PFkoRjJ5OEGwOVg6RC:jPh?=
LNCAP MnfqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MWizJIRigXN? MojnTWM2OCB;IEGyMlUh|ryP M4jvSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUG3PFk4Lz5{OUGxO|g6PzxxYU6=
LNCaP M33y[GFvfGGpb37pd5Qh[WO2aY\peJkh[XO|YYm= MlO3NVQ1KGh? M3j3cWdKPTBiPTCxPE45QCEQvF2= MojqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{N{K4PVQoRjJ6MkeyPFk1RC:jPh?=
LNCaP-AR MlXMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEfoR2cyPDRiaB?= M3\tdGdKPTBiPTCxPE46KM7:TR?= MlriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkG1PFYoRjJ3MUKxOVg3RC:jPh?=
C4-2B M{H1OGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MoXTNVIhcA>? MY\JR|UxKD1iMkCuO|ch|ryP MlrjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
A31 NXrTcIRiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYm3NkBp MnXqS2k2OCB;IEK3MlUh|ryP M4LsfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEGxNlE6Lz5{OECxNVIyQTxxYU6=
22Rv1 MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NH3oNng6PiCq NVq2b4lbUUN3MDC9JFMyNjd4IN88US=> NHTuVFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{OwNVM3QCd-MkezNFE{Pjh:L3G+
22Rv1 NGn4[oRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MW[5OkBp M3:2XmlEPTBiPTCzNU44PiEQvF2= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4NUi2Nkc,OjZ7NkW4OlI9N2F-
DU145 M2fUTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MWC5OkBp NV;BUIhFUUN3MDC9JFMzNjJ5IN88US=> M{m3XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{CxN|Y5Lz5{N{OwNVM3QDxxYU6=
LNCAP NF7reFdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M{XnZlczKGh? NGGxT2RKSzVyIE2gN|MvQDRizszN NX3jWpJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OFgyOzlpPkK5OFQ5OTN7PD;hQi=>
CW22Rv1 MYTBcpRi\2:waYP0JIFkfGm4aYT5JIF{e2G7 MVS3NkBp NXz3[ppFUUN3MDC9JFM2Njd3IN88US=> M1jiR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkeyPFk1Lz5{OEK3Nlg6PDxxYU6=
22Rv1 M2DmPGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NIn0dVk4OiCq MWHJR|UxKD1iM{[uOlYh|ryP MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR2OEGzPUc,Ojl2NEixN|k9N2F-
22Rv1 NIKxbWtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MkPWNVIhcA>? NFfSN2VKSzVyIE2gN|YvPjZizszN MofuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
LNCAP NU\mb2JYSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MYSxNkBp NYnsOlE5UUN3MDC9JFQzNjN5IN88US=> NV3LXnJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O|U5PTF6PD;hQi=>
DU145 Mn3URY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M{OybVMh\GG7cx?= NGi4V4hKSzVyIE2gOFYvOSEQvF2= NWLTfoVGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4NVA2QDlpPkK3PFExPTh7PD;hQi=>
DU145 M1nI[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MXyzJIRigXN? MYjJR|UxKD1iNE[uNUDPxE1? NW\lW4NvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxNVc5QTdpPkK5NVE4QDl5PD;hQi=>
Assay
Methods Test Index PMID
Western blot AR / ERG / NOTCH1 / PSA / Cleaved PARP1 / Cleaved caspase 7 ; AR-FL / AR-v7 / pAR(S213) / pAkt(S473) / pMdm2(S166) ; CXCR7 28607007 26378044 29277895
Growth inhibition assay Cell proliferation 28115200
Immunofluorescence AR ; pAKT(S473) ; CXCR7 27588408 29277895
ELISA osteoprotegerin 27015557
In vivo Enzalutamide induces great tumor regression in castrate male mice bearing LNCaP/AR xenografts at a dose of 10 mg/kg. [1]

Protocol (from reference)

Kinase Assay:[3]
  • AR reporter assay:

    Enzalutamide is evaluated by an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells are engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells are also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer. The antagonistic activity of Enzalutamide is tested in the presence of 100 pM of R1881. Engineered LNCaP cells are maintained in Iscove's medium containing 10% fetal bovine serum (FBS). Two days prior to Enzalutamide treatment, the cells are grown in Iscove's medium containing 10% charcoal-stripped FBS (CS-FBS) to deprive of androgens. The cells are split and grown in Iscove's medium containing 10% CS-FBS with 100 pM of R1881 and increasing concentrations of Enzalutamide. After two days of incubation, reporter activities are assayed.

Cell Research:[1]
  • Cell lines: LNCaP or LNCaP/AR cells
  • Concentrations: 0-10 μM
  • Incubation Time: 1-4 days
  • Method: Enzalutamide is diluted in DMSO. LNCaP or LNCaP/AR cells (104 cells/well) are androgen-starved by growth in media containing 5-10% charcoal-stripped serum for 3-5 days. Then the cells are challenged with various concentrations of Enzalutamide in media containing 5-10% charcoal-stripped serum.
Animal Research:[1]
  • Animal Models: Castration-resistant LNCaP/HR xenografts in male SCID mice
  • Dosages: 10 mg/kg
  • Administration: Administered via gavage daily

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 464.44
Formula

C21H16F4N4O2S

CAS No. 915087-33-1
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05191017 Not yet recruiting Drug: NUV-422|Drug: Enzalutamide Prostate Cancer|Prostatic Cancer|Cancer of Prostate|Cancer of the Prostate|Prostate Neoplasm|Castrate Resistant Prostate Cancer|Castration Resistant Prostatic Cancer|Castration Resistant Prostatic Neoplasms Nuvation Bio Inc. April 2022 Phase 1|Phase 2
NCT05081193 Not yet recruiting Drug: Testosterone Undecanoate|Drug: Enzalutamide Prostate Cancer|Castration-resistant Prostate Cancer|Metastatic Castration-resistant Prostate Cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Clarus Therapeutics February 15 2022 Phase 2
NCT04335682 Recruiting Drug: Darolutamide|Drug: Enzalutamide Metastatic Prostate Cancer|Prostate Cancer Metastatic|Prostate Cancer|Castrate Resistant Prostate Cancer Alliance Foundation Trials LLC.|Bayer August 17 2021 Phase 2
NCT04655365 Not yet recruiting Drug: Enzalutamide capsule Prostate Cancer CHU de Quebec-Universite Laval|Astellas Pharma Europe Ltd. January 4 2021 Phase 2
NCT04456049 Not yet recruiting Drug: Enzalutamide COVID-19 Infection Ricardo Pereira Mestre|Oncology Institute of Southern Switzerland|Institute of Oncology Research|Institute for Research in Biomedicine|Ente Ospedaliero Cantonale Bellinzona July 2020 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Enzalutamide (MDV3100) | Enzalutamide (MDV3100) supplier | purchase Enzalutamide (MDV3100) | Enzalutamide (MDV3100) cost | Enzalutamide (MDV3100) manufacturer | order Enzalutamide (MDV3100) | Enzalutamide (MDV3100) distributor